$3.34
-0.05[-1.47%]
At close: Apr 24
$3.34
0[0.00%]
After Hours: 4:50PM EDT
Gain Therapeutics
(NASDAQ:GANX)Latest News for Gain Therapeutics Stock (NASDAQ:GANX)
Gain Therapeutics Stock (NASDAQ: GANX)
Categories: All
Wednesday, April 24, 2024
Tuesday, April 23, 2024
Monday, April 08, 2024
Tuesday, April 02, 2024
Monday, April 01, 2024
Wednesday, March 27, 2024
Tuesday, March 26, 2024
Tuesday, March 05, 2024
- Market-Moving News for March 5thBenzinga Newsdesk - Mar 5, 2024, 8:33AM
- EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's DiseaseVandana Singh - Mar 5, 2024, 7:45AM
- EXCLUSIVE: Gain Therapeutics Tells Benzinga 'Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction'Benzinga Newsdesk - Mar 5, 2024, 7:45AM
- EXCLUSIVE: Gain Therapeutics Tells Benzinga Co. Will Present Data At The AP/PD 2024 Conference On Mar. 8 And 9 Demonstrating Mechanism Of Action Of GT-02287, Its Regulator GCase Regulator For The Treatment Of Parkinson's DiseaseBenzinga Newsdesk - Mar 5, 2024, 7:45AM
Tuesday, February 27, 2024
Tuesday, February 06, 2024
Wednesday, January 31, 2024
Tuesday, January 16, 2024
Monday, December 04, 2023
Friday, December 01, 2023
Tuesday, November 21, 2023
- Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Nov 21, 2023, 1:28PM
- Gain Therapeutics shares are trading lower after the company announced a $9.4 million public offering of 2,213,044 shares at $2.005 per share and a concurrent private placement of 2,500,088 shares at $2 per share.Benzinga Newsdesk - Nov 21, 2023, 11:49AM
- Gain Therapeutics Announces Pricing Of $9.4M Public Offering Of 2,213,044 Shares At $2.005/Share And Accompanying Warrants; Concurrent Private Placement With Completion Of Public Offering Of 2,500,088 Shares At $2/ShareBenzinga Newsdesk - Nov 21, 2023, 8:57AM
Monday, November 20, 2023
Wednesday, October 04, 2023
Monday, September 18, 2023
Tuesday, September 12, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023Benzinga Insights - Sep 12, 2023, 11:00AM
- Maxim Group Initiates Coverage On Gain Therapeutics with Buy Rating, Announces Price Target of $10Benzinga Newsdesk - Sep 12, 2023, 9:50AM
- Gain Therapeutics Receives Approval To Commence Phase 1 Clinical Study Of GT-02287 From The Human Research Ethics Committee In AustraliaBenzinga Newsdesk - Sep 12, 2023, 9:27AM
Thursday, August 31, 2023
Monday, August 14, 2023
Thursday, August 10, 2023
Tuesday, June 27, 2023
- Director at Gain Therapeutics Acquires Company Stock Options Worth 10,500 SharesBenzinga Insights - Jun 27, 2023, 11:03AM
- Board Member at Gain Therapeutics Acquires Company Stock Options Worth 10,500 SharesBenzinga Insights - Jun 27, 2023, 11:03AM
- Gain Therapeutics Director Awarded $46K Worth of Stock OptionsBenzinga Insights - Jun 27, 2023, 11:03AM
- Gain Therapeutics Board Member Awarded $46K Worth of Stock OptionsBenzinga Insights - Jun 27, 2023, 11:03AM
Monday, June 12, 2023
Monday, May 15, 2023
- Chardan Capital Maintains Buy Rating for Gain Therapeutics: Here's What You Need To KnowBenzinga Insights - May 15, 2023, 1:00PM
- Where Gain Therapeutics Stands With AnalystsBenzinga Insights - May 15, 2023, 11:01AM
- Analyst Expectations for Gain Therapeutics's FutureBenzinga Insights - May 15, 2023, 8:02AM
- HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $10 Price TargetBenzinga Newsdesk - May 15, 2023, 7:02AM
- Chardan Capital Maintains Buy on Gain Therapeutics, Raises Price Target to $6Benzinga Newsdesk - May 15, 2023, 4:07AM